PharmaCyte exchanges warrants for shares and extends maturity
PharmaCyte Biotech will exchange 851,304 warrants for 4,982,272 shares and has agreed to extend the Series H preferred stock maturity. The extension was secured via the consent of the holder, who controls a majority of the Series H stock.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed